{
    "clinical_study": {
        "@rank": "116027", 
        "arm_group": [
            {
                "arm_group_label": "NAV5001", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "DaTscan", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a phase 3, open-label, multiple-center, randomized cross-over study to assess the\n      safety and efficacy of [123I]NAV5001 SPECT imaging in aiding in the differentiaion of\n      parkinsonian syndromes from non-parkinsonian tremor."
        }, 
        "brief_title": "A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Parkinson's Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Parkinson Disease", 
                "Parkinsonian Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has provided written informed consent before the initiation of any study\n             related procedures and continues to give willing consent for participation\n\n          -  Age \u2265 40  years\n\n          -  Have had upper extremity tremor for < 3 years duration, regardless of presumed\n             diagnosis or etiology\n\n          -  Have a UPDRS part III score upon entry of \u2264 16\n\n        Exclusion Criteria:\n\n          -  Any clinically significant or unstable physical or psychological illness based on\n             medical history or physical examination at screening, as determined by the\n             investigator\n\n          -  Structural brain abnormality affecting the entire brain (e.g., normal pressure\n             hydrocephalus) or the striatum (e.g., local tumor or stroke)\n\n          -  Any clinically significant abnormal laboratory results obtained at screening and as\n             determined by the investigator\n\n          -  Any clinically significant abnormal electrocardiogram (ECG) results obtained at\n             screening and as determined by the investigator\n\n          -  Any history of drug, narcotic, or alcohol abuse within 2 years before the date of\n             informed consent, as defined by the Diagnostic and Statistical Manual of the American\n             Psychiatric Association, Fourth Edition, revised (DSM-IV-TR [American Psychiatric\n             Association, 1994])\n\n          -  Positive urine drug screen for opiates, cocaine, or amphetamines at screening\n\n          -  Positive pregnancy test before imaging\n\n          -  Participation in an investigational drug or device clinical trial within 30 days\n             before the date of informed consent\n\n          -  Previous scan with any DAT imaging agent (e.g. [123I]NAV5001, Altropane, DaTscan,\n             DOPASCAN)\n\n          -  Any exposure to radiopharmaceuticals within 30 days before the date of informed\n             consent\n\n          -  Breast-feeding\n\n          -  Inability to lie supine for 1 hour\n\n          -  Any thyroid disease other than adequately treated hypothyroidism\n\n          -  Known  sensitivity or allergy to iodine or iodine containing products\n\n          -  Treatment within the 30 days before the date of imaging with amoxapine, amphetamine,\n             benztropine, bupropion, buspirone, cocaine, mazindol, methamphetamine,\n             methylphenidate, norephedrine, phentermine, phenylpropanolamine, selegiline, and\n             sertraline, paroxetine, or citalopram."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "275", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01950468", 
            "org_study_id": "NAV5-02"
        }, 
        "intervention": [
            {
                "arm_group_label": "NAV5001", 
                "description": "A single intravenous dose of 8.0 \u00b1 1.0 mCi", 
                "intervention_name": "NAV5001", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "DaTscan", 
                "description": "A single intravenous dose of 3 to 5 mCi", 
                "intervention_name": "DaTscan", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Parkinson's Disease", 
        "lastchanged_date": "January 23, 2014", 
        "location": [
            {
                "contact": {
                    "email": "larmijo@xenoscience.com", 
                    "last_name": "Laura Armijo", 
                    "phone": "602-274-9500"
                }, 
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85004"
                    }, 
                    "name": "Xenoscience, Inc."
                }, 
                "investigator": {
                    "last_name": "Stephen Flitman, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "DMarsh@CompassResearch.com", 
                    "last_name": "Dan Marsh", 
                    "phone": "407-210-1310"
                }, 
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "Compass Research"
                }, 
                "investigator": {
                    "last_name": "Ira Goodman, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes", 
        "other_outcome": {
            "measure": "The incidence of positve DaTscan SPECT brain scans", 
            "safety_issue": "No", 
            "time_frame": "Baseline"
        }, 
        "overall_contact": {
            "email": "jsanders@navidea.com", 
            "last_name": "James Sanders", 
            "phone": "(614) 973-7464"
        }, 
        "overall_official": {
            "affiliation": "Navidea Biopharmaceuticals", 
            "last_name": "Cornelia Reininger, M.D. Ph.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "The incidence of Parkinson' Syndrome based on the Movement Disorder Specialist Consensus Panel", 
                "safety_issue": "No", 
                "time_frame": "One Year"
            }, 
            {
                "measure": "The incidence of positve [123I]NAV5001 SPECT brain scans", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "measure": "The incidence of Parkinson' Syndrome based on the on-site neurologist assessment", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01950468"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The incidence of Parkinson' Syndrome based on the on-site neurologist assessment at 6 months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "The incidence of Parkinson' Syndrome based on the on-site neurologist assessment at 1 year", 
                "safety_issue": "No", 
                "time_frame": "1 Year"
            }, 
            {
                "measure": "Incidence of adverse events post baseline", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Navidea Biopharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Navidea Biopharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}